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Abstract
Background: It has recently been demonstrated that the fate of adult cells is not restricted to
their tissues of origin. In particular, it has been shown that bone marrow stem cells can give rise to
cells of different tissues, including neural cells, hepatocytes and myocytes, expanding their
differentiation potential.
Results: In order to identify factors able to lead differentiation of stem cells towards cells of neural
lineage, we isolated stromal cells from human adult bone marrow (BMSC). Cells were treated with:
(1) TPA, forskolin, IBMX, FGF-1 or (2) retinoic acid and 2-mercaptoethanol (BME). Treatment (1)
induced differentiation into neuron-like cells within 24 hours, while a longer treatment was
required when using retinoic acid and BME. Morphological modifications were more dramatic after
treatment (1) compared with treatment (2). In BMSC both treatments induced the expression of
neural markers such as NF, GFAP, TUJ-1 and neuron-specific enolase. Moreover, the transcription
factor Hes1 increased after both treatments.
Conclusion: Our study may contribute towards the identification of mechanisms involved in the
differentiation of stem cells towards cells of neural lineage.
Background
Up until only a few years ago, the fate of adult stem cells
was believed to be limited to their tissue of origin. How-
ever, it has recently been demonstrated that in several tis-
sues adult stem cells may undergo a fate other than that
habitually manifested in physiological conditions. As an
example, stem cells isolated from bone marrow can differ-
entiate not only into blood cells, but also into hepatocytes
[1], skeletal muscle [2] and cardiomyocytes [3]. Even
more surprisingly, recent studies have shown that stem
cells in vivo may even give rise to neural cells, thus repre-
senting an important alternative to embryonic cells for
therapeutic transplantation [4,5]. Indeed, the original
idea of substituting neurons damaged by different patho-
logical events with undamaged heterologous neurons has
not so far afforded satisfactory results [6,7]. On the other
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hand, although the discovery of the existence of neural
stem cells in the adult human brain [for a review see [8]]
is certainly a milestone in the field, it is difficult to con-
ceive a method leading to manipulation and reimplanta-
tion of neural stem cells taken directly from the patient's
brain. Accordingly, the source represented by bone mar-
row offers theoretically unlimited therapeutical applica-
tions.
Two major subpopulations of stem cells can be identified
in bone marrow: hematopoietic stem cells, which give rise
to red blood cells, platelets, monocytes, granulocytes and
lymphocytes, and non-hematopoietic stromal cells
(BMSC), more recently acknowledged to be of a mesen-
chymal nature due to their capacity to differentiate into
myogenic, osteogenic, chondrogenic and adipogenic line-
ages [9,10]. BMSC can be isolated from whole bone mar-
row by adherence to plastic culture dishes. Recent studies
have shown that BMSC can be induced to express a neu-
ronal phenotype in vitro under specific experimental con-
ditions. For example, Woodbury et al. [11] observed that
in the presence of β-mercaptoethanol and dimethylsul-
foxide BMSC may differentiate into cells expressing neu-
ron specific enolase (NSE) and neurofilament. Moreover,
it has been described that in the presence of epidermal
growth factor (EGF) and brain-derived neurotrophic fac-
tor (BDNF) stromal cells differentiate into neural cells
that express both neuronal and glial markers (Neu-N, nes-
tin, GFAP) [12]. Deng et al. [13] demonstrated how fac-
tors that increase intracellular cAMP induce the
differentiation of BMSC into early progenitors of neural
cells. Unfortunately, due to the differences in BMSC isola-
tion and culture conditions, as well as in characterization
of differentiated cells, it is not possible to compare these
treatments. For this reason, we examined the different
effects produced by two specific treatments in inducing
differentiation of BMSC into neural phenotype. Recent
studies show that the transcription factors with helix-loop
helix (bHLH) motifs [for review see: [14,15]] are essential
for maintenance of neural precursor cells in an undiffer-
entiated state. bHLH genes include the mammalian Hairy
and Enhancer of Split genes (Hes1, Hes3 and Hes5); in
particular Hes1 is highly expressed by neural stem cells
[15,16]. Our results show that Hes1 is involved in BMSC
differentiation into neural cells. In fact a transient increase
of this transcription factor was observed in neural precur-
sors after both treatments.
Results
BMSC characterization
BMSC were isolated from human bone marrow aspirates
and propagated in culture. To characterize these cells, flu-
orescent cell sorting was performed using antibodies
against mesenchymal cell surface markers, such as CD90,
CD105 and CD73. Cells were positive for all these mark-
ers, showing a typical mesenchymal-like immunopheno-
type (fig. 1). On the other hand they were negative for
CD34, CD11b and CD13, markers associated with hemat-
opoietic cells (data not shown).
Induction of neural phenotype
Cellular morphology
Undifferentiated BMSC displayed a flat morphology with
short processes (fig. 2a). To identify conditions that may
induce differentiation towards a neural phenotype, two
different in vitro treatment protocols were used. When
cells were treated with treatment 1, a cocktail of fibroblast
growth factor-1 (FGF-1) and co-activating substances such
as TPA (protein kinase C (PKC) activator), IBMX and for-
skolin (protein kinase A (PKA) activator), their morphol-
ogy, observed by contrast phase and scanning electron
microscopy, changed rapidly. Indeed, after 5 hours (fig.
2b), cytoplasm was observed to have retracted toward the
FACS analysis of BMSC Figure 1
FACS analysis of BMSC. The percentage of positive cells for 
CD105 (a), CD90 (b) and CD73 (c) is indicated in the lower 
right-hand corner of each graph. (d) negative control.BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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Phase-contrast photomicrograph of BMSC and those exposed to treatment 1 or to treatment 2 for 3 (e) and 7 days (f) Figure 2
Phase-contrast photomicrograph of BMSC and those exposed to treatment 1 or to treatment 2 for 3 (e) and 7 days (f). In 
untreated cultures (a), BMSC showed a large, flat morphology. After 5 hours (b) of treatment 1 and even more after 24 hours 
(c), cells had morphological features typical of neurons, such as spherical shape and extending processes; this morphology also 
persisted at 48 hours of treatment (d). The treatment 2 determined, after 3 days, an increase of cell density (e). After 7 days (f) 
cells with a spindle-shaped morphology could be observed. Bar: 80 µm.BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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nucleus in some cells, taking on a more spherical shape
and extending processes. The percentage of cells modify-
ing morphology increased progressively up to 24 hours
(fig. 2c). Subsequently, proliferation in these cells came to
a halt and after 48 hours (fig. 2d) of treatment a senescent
morphology was evidenced. These modifications were
more evident at scanning electron microscopy (fig. 3).
When differentiation factors were removed from medium,
cell morphology reverted to the original BMSC shape
(data not shown). On the contrary, treatment 2 (retinoic
acid and BME) did not determine similarly rapid and dra-
matic changes: as shown in fig. 2e, an increase of cell den-
sity with consequent morphological modifications could
be observed only after 3 days. After 7 days (fig. 2f) the
majority of cells were seen to have assumed a spindle-
shaped morphology which persisted for up to 10 days fol-
lowing treatment (data not shown).
RT-PCR
The expression of neural genes in both undifferentiated
and differentiated BMSC was examined in order to verify
the occurrence of neural differentiation after treatment.
Total mRNA was extracted from untreated and treated
cells and analyzed by RT-PCR (fig. 4). Nestin mRNA was
present in undifferentiated BMSC, although expression
was observed to have decreased in a significant and pro-
gressive manner at 24 and 48 hours after treatment 1.
GFAP and NSE were weakly expressed prior to both treat-
ments, although treatment 1 determined for both pro-
teins a significant increase at 24 hours and then
subsequently a decrease. No significant differences in
vimentin and neurofilament mRNA levels were revealed
by RT-PCR analysis between controls and treated cells
after treatment 1. When BMSC were treated with retinoic
acid, no change was observed in nestin mRNA levels
respect to controls. However, retinoic acid led to a signifi-
cant decrease of vimentin, while GFAP, NF and NSE
mRNA levels were not modified.
RT-PCR for Hes1 was performed in untreated and treated
BMSC. The graph in fig. 4 shows that Hes1 was expressed
at low levels in undifferentiated BMSC, but its mRNA lev-
els significantly increased after 5 hours of treatment1.
Hes1 expression tended to decrease as neural differentia-
tion proceeds. In fact, after 24 h and 48 h of treatment 1,
mRNA levels were not significantly different as compared
to undifferentiated cells. At the same manner, treatment 2
determined a significant increase of Hes1 expression after
7 days.
Western blot
Western blot analysis of cultures revealed how both treat-
ments had modified the expression of specific neural
markers. As shown in fig. 5, untreated BMSC were positive
for vimentin and displayed a weak expression of nestin, a
marker for neural precursor. Cells were negative for other
neural markers, such as NF, GFAP and TUJ-1. A strong
expression of nestin was observed in treated cells at five
hours from treatment 1, which was subsequently fol-
lowed by a decrease in levels of this protein. Treatment 1
also induced expression of neurofilaments, which were
seen to be present after 5 hours and to have further
increased at 48 hours. On observation at 5 hours from
treatment 1 GFAP was already present, with a progressive
increase having occurred at 24 and 48 hours. Moreover, a
strong expression of TUJ-1 appeared after 5 hours and was
maintained until 48 hours from treatment 1. However, an
opposite trend was displayed by vimentin which
decreased from control to 48 hours. Following treatment
with retinoic acid, vimentin was negative (data not
shown), although after 7 days this treatment produced an
increase in nestin, neurofilaments, GFAP and TUJ-1.
Immunocytochemistry
Immunocytochemistry was performed to investigate cel-
lular localization of neuronal markers. Analysis con-
firmed that immunoreactivity for specific neural markers
had been induced by both treatments (fig. 6). Nestin was
present in untreated BMSC (A1) and had increased 5
hours after treatment 1 (A2). On the contrary, by means
of cell differentiation (24–48 hours), a decrease of stain-
ing intensity was registered for the expression of nestin
(A3,4). GFAP immunoreactivity, absent in untreated cells
(B1), was manifested 5 hours after treatment 1 and per-
sisted until 24 hours after treatment (B2,3). Immunos-
taining for neurofilaments was totally absent in untreated
BMSC (C1), although after treatment 1 immunoreactivity
was visible in some cell bodies and processes (C2,3),
more evident at higher magnification (C3 insert). Neu-
ron-specific enolase expression (fig. 7) had already been
induced by PK activators 5 hours after treatment and per-
sisted after 24 hours. Treatment 2 determined strong
GFAP (B4) and neurofilament (C4) immunostaining in
several cells after 7 days. On the other hand, nestin immu-
nostaining was not modified by this treatment (A4).
Discussion
Several recent studies have suggested that stromal cells
from bone marrow may be capable of generating either
neurons or glia, both in vivo [4,5] and in vitro [12].
In this study we induced stromal cells from human bone
marrow to differentiate into cells with a neural pheno-
type, comparing two different protocols. Furthermore, we
explored for the first time the involvement of the tran-
scription factor Hes1 in inducing neural phenotype in
BMSC. Both treatments led to a neural phenotype in a
similar but not identical manner. Indeed, at the end of
both treatments, BMSC expressed neural markers such as
NF, TUJ-1 and GFAP, whereas nestin and vimentin pro-BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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gressively decreased with differentiation. These results
were associated with different morphological modifica-
tions and required times of exposure ranging from one
day to one week, depending on the treatment. The first
induction media (a cocktail of PKC and PKA activators
and FGF-1) rapidly determined dramatic modifications of
cell shape and induced the expression of several neural
markers in less than 24 hours. Differentiation was tran-
sient and cells reverted to their original phenotype when
the inducing factors were removed. On treating BMSC
with retinoic acid and BME biochemical markers consist-
ent with differentiation towards a neural phenotype were
not expressed before seven days. Moreover, morphologi-
cal changes were not as drastic as in the other treatment,
although differentiation persisted even when inducing
agents were removed.
It is well known that an increase of intracellular cAMP and
consequent PKA activation represents a critical regulator
for differentiation of neurons and glia [17]. Moreover,
agents that increase intracellular cAMP levels induce neu-
roendocrine differentiation in human prostate carcinoma
cells [18], neuronal differentiation in C6 glioma cells
[19,20] and processes elongation in MCD-1 medulloblas-
toma cell line [21]. In the same manner, PKC is involved
in neural differentiation regulating neurite outgrowth and
branching [22,23]. Iacovitti et al. [24] showed that FGF-1,
together with co-activator molecules such as dopamine,
PKA and PKC activators, induced differentiation of an
embryonic carcinomal stem cell line into dopamine neu-
rons. Deng et al. [13] found that human BMSC can be dif-
ferentiated into early neural progenitors by conditions
that increase intracellular cAMP. After six days of treat-
ment these cells expressed NSE and vimentin but not
markers of mature neurons, such as NF-M or MAP-2. In
our experiments, treatment 1 induced BMSC to differenti-
ate into more mature neuron-like cells within 24 hours.
Retinoic acid (RA), a derivative of vitamin A, is essential
in maintaining normal cellular growth and development.
In fact, RA is present in various tissues of both embryonic
and adult animals, in particular in the nervous system [25-
30], where it promotes neuronal differentiation [31]. Pre-
vious studies have demonstrated that RA induces both a
greater number of neurites as well as increased neurite
length in cultured neurons [for a review, see [32]]. Retin-
oic acid has been used in combination with other factors
to induce differentiation of BMSC into neural cells [12,33-
35]. Since it has been suggested that BME is capable of
supporting the viability and differentiation of fetal mouse
brain neurons [36], we used low concentrations of this
factor in combination with retinoic acid (treatment 2).
With this treatment, BMSC slowly differentiated into neu-
ron-like cells and after 7 days they expressed NF-M. Cells
survived in induction media for up to at least 14 days.
These results confirmed data reported by other authors
suggesting that BMSC are able to differentiate in cell types
of varying embryonic origin. In particular, using two dif-
ferent treatments we induced BMSC to differentiate into
cells with neuronal phenotype. At the end of both treat-
ments cells expressing neural markers such as neurofila-
ment and GFAP were obtained, whereas vimentin and
nestin decreased with differentiation. The presence of
GFAP in treated BMSC may be ascribed not only to differ-
entiation into astrocytes, but also to neural precursors,
that have been demonstrated to express this protein [37].
Prior to inducing differentiation, BMSC expressed nestin,
a commonly used marker of neural precursor. A transient
expression of this intermediate filament in non-neural
cells, such as hepatic stellate cells, myogenic and epithe-
lial cells has recently been observed [38,39]. Moreover, in
our experiments the patterns of mRNA and protein
expression did not exactly match. For example, mRNA for
neurofilaments was present in BMSC and was not modi-
fied during differentiation, whereas the protein was
Scanning electron microscopy (SEM) of untreated BMSC (A)  and after 24 h of treatment 1 (B) Figure 3
Scanning electron microscopy (SEM) of untreated BMSC (A) 
and after 24 h of treatment 1 (B). Bar: 20 µm (B).BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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absent in untreated cells and its expression was induced
by treatments. These data suggest that the expression of
neural markers (such as neurofilaments, nestin, GFAP,
NSE) is controlled at a translational rather than a tran-
scriptional level. In fact, the constitutive expression of
these proteins by BMSC confirms the hypothesis that
these cells are "multidifferentiated" cells and thus can
retain the ability for neuronal differentiation, as already
suggested by Tondreau et al. [40].
Microscopic examination of the cultures revealed that,
using either of the two protocols, only a small percentage
of cells (15–20%) showed immunoreactivity for neural
markers, suggesting that only a subset of BMSC can differ-
RT-PCR for neural markers in BMSC after normalization to GADPH Figure 4
RT-PCR for neural markers in BMSC after normalization to GADPH. Treatment 1 induced a significant decrease in nestin 
mRNA and an increase in GFAP and NSE expression after 24 h of treatment; Hes1 expression increased after 5 h and it was 
reduced during differentiation (24 h, 48 h). Vimentin and neurofilament mRNA levels were unchanged. On the contrary, after 
7 days of treatment 2 only vimentin mRNA expression significantly decreased. Moreover, treatment 2 determined a significant 
increase in Hes1 mRNA expression after 7 days; no change was observed in other mRNA levels respect to controls. *P < 0.05 
vs. control, (n = 4).BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
Page 7 of 12
(page number not for citation purposes)
entiate into cells with a neural phenotype. We can there-
fore hypothesize that this subfraction of BMSC may be
constituted by tissue-specific progenitor cells with
restricted differentiation potential, capable of giving rise,
under specific experimental conditions, to cells character-
istically found in other tissues. In fact, morphological and
phenotypic heterogeneity of BMSC has been demon-
strated: BMSC include small round cells and large polygo-
nal-shaped cells with different multilineage potentials
[41,42]. On the other hand, our findings may indicate the
possibility that a population of multipotential stem cells
resides in adult bone marrow.
The results reported demonstrate how the microenviron-
ment may be capable of affecting cellular differentiation,
since activation of PKs alone leads to neuron-like cell
morphology, but the cells express neural markers after
both treatment protocols. This observation suggests that
specific marker expression is not always accompanied by
typical morphological modifications [5,43]. In contrast,
Black and Woodbury [44] have demonstrated that BME
induces stromal rat cells to differentiate into neuronal
phenotype cells, but at concentrations 10–100 times
higher than those used in the present study. In our exper-
iments, RA and BME concentrations were sufficient to
affect the expression of neural markers but not to induce
morphological modifications. The differences observed
between the two treatments respect to morphological
changes and to time required for differentiation may indi-
cate the activation of different intracellular molecular
mechanisms in these processes. It has been suggested that
the molecular mechanisms involved in the action of RA
during embryogenesis may occur via a complex signaling
pathway [for review see [45]]; moreover, it has been
hypothesized that both in vitro and in vivo, the number
of neural-specific genes encoding transcription factors
and signaling molecules induced by RA during neural dif-
ferentiation are comparable [46].
In a recent report Lu et al. [47] observed a neuron-like
morphology in BMSC exposed to various stressors. An
increase in NSE immunoreactivity was also observed, but
it could not be confirmed by RT-PCR, suggesting that
these modifications can be the result of cell shrinkage. On
the contrary, our results showed the increase of neural
markers not only by immunocytochemistry, but also by
RT-PCR and western blot.
Hes1 is a transcription factor that plays a key role in neu-
rogenesis regulation maintaining cortical progenitors by
inhibiting neurogenesis [15]. Our results show that after 5
hours of treatment 1, the expression of Hes1 transiently
increases. We could speculate that the upregulation of
Hes1 expression induces differentiation of BMSC into
neural precursors and its inhibition leads these cells to dif-
ferentiate into more mature cells, as observed in vivo dur-
ing development [16]. On the other hand, we observed an
increase of Hes1 expression after 7 days of treatment 2.
This result may indicate that retinoic acid treatment leads
cells to acquire a less mature phenotype as compared to
treatment 1. This hypothesis is confirmed by nestin
expression that decreases after treatment 1, but that is not
modified by treatment 2.
Conclusion
As summarized in the present report, it has been demon-
strated that different differentiation-inducing factors and
protocols are capable of generating neural cell types from
BMSC. Moreover, we observed a modulation of Hes1
expression with both treatment, suggesting an involve-
ment of this transcription factor in differentiation of
BMSC into neural cells. By combining these molecular
biological strategies and neuronal differentiation systems,
it should prove possible to detect, isolate, and characterize
specifically expressed genes involved in neuronal differen-
tiation. Our results suggest that adult bone marrow stem
cells may differentiate into cells with distinct glial or neu-
ronal phenotypes after exposure to specific signals or
modulating specific genes, such as Hes1, and thus consti-
tute a cellular reservoir for neurodegenerative diseases of
the central nervous system.
Western blot analysis of neural markers after treatment 1 or  2 of BMSC Figure 5
Western blot analysis of neural markers after treatment 1 or 
2 of BMSC. The results showed that both treatments pro-
duced an increase of neural markers respect to untreated 
cells. On the contrary, vimentin, well expressed in untreated 
BMSC, decreased from 5 to 48 hours of treatment 1.BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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Expression of nestin (A), GFAP (B) and neurofilament (C) in undifferentiated and differentiated BMSC Figure 6
Expression of nestin (A), GFAP (B) and neurofilament (C) in undifferentiated and differentiated BMSC. Untreated cells were 
labeled for nestin (A1), whose expression decreased with treatment 1 (A2,3) but persisted after treatment 2 (A4). GFAP 
immunoreactivity was negative in untreated cells (B1), but after 5 (B2) and 24 hours (B3) of treatment 1 some cells were GFAP 
positive. Treatment 2 determined strong GFAP immunostaining after 7 days (B4). Immunoreactivity for neurofilaments, totally 
absent in untreated BMSC (C1), was present in some cell bodies and processes after treatment 1 (C2,3; higher magnification in 
C3 insert) and treatment 2 (C4). Cells were also stained with Hoechst dye 33258. Bar: 40 µm. Insert bar: 10 µm.BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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Methods
Cell culture
20–40 ml bone marrow aspirates were taken from 10
healthy donors (age range 6–33 years) after obtaining of
informed consent. Mononuclear cells were separated by
gradient density using Ficoll-Hypaque and MSC selected
by plastic adhesion according to Lee et al. [48]. Briefly,
cells were seeded in culture flasks including α-MEM
(Cambrex) supplemented with 20% FCS and 10-8M vita-
min K. After 24 hours, 10-8M dexamethasone and 50 µg/
ml ascorbic acid were added without media change. Sub-
sequently, the culture flasks were left undisturbed for 4–5
days to promote cell attachment. After this time, the non-
adherent cells were removed by replacing the medium. At
near-confluence, cells were subcultured after trypsin
digestion.
Cell treatment
After at least four passages, cells were plated at a density of
2 × 104 cells/ml in a 10-cm plastic culture dish for western
blot and RT-PCR, and in 3.5-cm dishes containing glass
coverslips for immunocytochemistry and electron micro-
scopy. After 24 hours, cells were treated with two different
protocols:
treatment 1
10 ng/ml FGF-1 (R&D, Minneapolis, MN), 200 nM 12-O-
tetradecanoylphorbol-13-acetate (TPA; Sigma, St Louis,
USA), 250 µM IBMX (Sigma) and 50 µM forskolin
(Sigma), in DMEM/F12 (Sigma) 1:1 supplemented with
ITS (Sigma) 1%.
treatment 2
1 µM all-trans-retinoic acid (Sigma) and 100 µM 2-mer-
captoethanol in DMEM supplemented with 10% FCS
(Invitrogen).
At various time intervals, cultures were fixed for immuno-
cytochemistry and electron microscopy, or processed for
RT-PCR and western blot.
Immunocytochemistry
Cells on coverslips were fixed at -20°C with cold metha-
nol for 4 min. For staining, samples were rehydrated in
PBS/0.2% (v/v) Triton X-100 and pre-incubated with nor-
mal goat serum (1:5, Vector, Burlingame, CA, USA) for 30
min. Cells were then overlaid with the following primary
antibodies diluted in PBS/0.2% (v/v) Triton, for 60 min at
room temperature: monoclonal anti-nestin (1:100,
Chemicon, Temecula, CA, USA); polyclonal anti-GFAP
(1:200, DAKO, Carpinteria, CA, USA); polyclonal anti-
neurofilament 150 kDa (1:100, Chemicon). Texas red
conjugated anti-mouse IgG (1:200; Jackson ImmunoRe-
search, West Grove, PA, USA) or FITC conjugated anti-rab-
bit IgG (1:500; Molecular Probes, Eugene, OR, USA) were
used as secondary antibodies. After several washings sam-
ples were overlaid with Hoechst 33258. Negative controls
were incubated with non immune serum and with appro-
priate secondary antibody.
In other experiments, cells were incubated with 1% phe-
nylhydrazine hydrochloride (Sigma) to block endog-
enous peroxidase for 30 min and then with monoclonal
antibodies against neuron specific enolase (NSE; 1:20,
Cymbus Biotechnology) for 60 min at room temperature.
Subsequently, slides were rinsed three times in PBS-Tri-
ton, incubated for 30 min with biotinylated antimouse
IgG (1:200, Vector), rinsed and incubated with avidin D-
conjugated horseradish peroxidase (1:800, Vector) fol-
lowed by 10 min incubation with DAB tablet sets (SIGMA
FAST). Negative controls were incubated with non
immune serum instead of primary antibody.
Immunocytochemical staining of BMSC for NSE after 5 and 24 hours of treatment 1 Figure 7
Immunocytochemical staining of BMSC for NSE after 5 and 24 hours of treatment 1. Treated cells expressed high levels of NSE 
compared to those untreated. Bar: 20 µm.BMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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Western Blot
Cells were lysed with sodium dodecyl sulphate (SDS) 2%.
Protein concentration was measured according to the
method of Lowry [49]. Loading buffer (75 mM Tris-HCl,
pH 6.8, 20 % glycerol, 5% 2-mercaptoethanol, 0.001
bromophenol blue) was subsequently added and samples
were placed in boiling water for 3 min. 15–30 µg of pro-
tein were run on 10% or 5% SDS-polyacrilamide gel,
depending on molecular weight. Separated proteins were
electroblotted onto PVDF membrane (Hybond-P, Amer-
sham) and blocked with 5% nonfat dry milk overnight at
4°C. Immunodetection was performed with antibodies
against nestin (1:1000, monoclonal, Chemicon, Temec-
ula, CA, USA), GFAP (1:5000, polyclonal, DAKO, Carpin-
teria, CA, USA), neurofilament (1:5000, polyclonal,
Chemicon), vimentin (1:1000, monoclonal, DAKO,
Carpinteria, CA, USA), NSE (1:5000, monoclonal, Cym-
bus Biotechnology), TUJ-1 (β-III tubulin; 1:500, mono-
clonal, Chemicon) and GAPDH (1:600, monoclonal,
Chemicon). The membrane was washed and incubated
with a horseradish peroxidase conjugated anti-mouse IgG
(1:1000, Chemicon) or anti-rabbit IgG (1:5000, Chemi-
con). After washing, protein bands were detected with
SuperSignal West Pico chemiluminescent substrate
(Pierce).
Reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA was isolated from cell cultures using Trizol rea-
gent (Gibco) according to the method of Chomczynski
[50]. The RNA concentration was measured in a spectro-
photometer at 260 nm. Identical amounts of RNA were
reverse transcribed into cDNA. cDNA was subsequently
amplified by the polymerase chain reaction (PCR) with
specific primers (Table 1). To obtain quantitative PCR
with a non radioactive label, digoxigenin-11-dUTP (DIG)
(Roche) was incorporated during PCR reaction. An aliq-
uot of the PCR reaction mixture was electrophoresed in
3% agarose gels in Tris-borate/EDTA buffer to allow ade-
quate separation of the cDNA. cDNA was transferred to a
nylon membrane by blotting for 16 h in 10 × SSC. The
blot was washed briefly in buffer A (maleic acid, 0.1 M;
sodium chloride 0.15 M, pH 7.5, plus Tween 20, 0.3%)
and incubated for 30 min at room temperature in block-
ing buffer (1% blocking reagent, Roche, in buffer A). This
was followed by a 30 min incubation period with an anti-
digoxigenin-IgG conjugated to alkaline phosphatase
(Roche) diluted in blocking buffer. The blot was washed
and chemiluminescent detection performed by incubat-
ing the membrane for 5 min in a CSPD solution (Roche).
The membrane was sealed in a clear plastic bag and
exposed to X-ray film (KODAK X-OMAT) 2–10 min in an
X ray cassette at room temperature. Signals corresponding
to each molecule of interest and GAPDH mRNA were
scanned using a densitometer (Hoefer Scientific Instru-
ments, San Francisco, CA, U.S.A.). mRNA amounts were
normalized by comparison with GAPDH levels. Differ-
ences in mRNA amounts between control and treated cells
were evaluated using Student's t test for paired samples.
Table 1: Primer sequences and cycling conditions in RT-PCR
Lenght of amplified Primer sequences Cycles
Nestin 220 bp 5'GCCCTGACCACTCCAGTTTA3'
5'GGAGTCCTGGATTTCCTTCC3'
33 cycles:
30 sec, 94°C
30 sec, 55°C
30 sec, 72°C
Vimentin 200 bp 5'GGGACCTCTACGAGGAGGAG3'
5'CGCATTGTCAACATCCTGTC3'
30 cycles:
30 sec, 94°C
30 sec, 55°C
30 sec, 72°C
NF-M 333 bp 5'TGGGAAATGGCTCGTCATTT3'
5'CTTCATGGAAGCGGCCACTT3'
35 cycles:
30 sec, 94°C
60 sec, 55°C
90 sec, 72°C
NSE 329 bp 5'TGAACACAGACGCTATGCGCTCAG3'
5'CACCTTTATGTGAGTGGACACAGA3'
30 cycles:
60 sec, 94°C
60 sec, 60°C
120 sec, 72°C
Hes1 349 bp 5'ACACGACACCGGATAAACCAA3'
5'CGAGTGCGCACCTCGGTA3'
25 cycles 
30 sec, 94 °C
30 sec, 60 °C
30 sec, 72 °C
GAPDH 347 bp 5'GCCAAAAGGGTCATCATCTCTG3'
5'CATGCCAGTGAGCTTCCCGT3'
25 cycles:
30 sec, 96°C
60 sec, 58°C
30 sec, 74°CBMC Neuroscience 2006, 7:14 http://www.biomedcentral.com/1471-2202/7/14
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Fluorescence-activated cell sorting (FACS)
For surface protein expression, BMSC were detached with
0.5% trypsin for 10–15 min. at 37°C, washed, counted
and resuspended in 0.1% BSA/PBS and incubated with
the following primary antibodies: monoclonal phyco-
erythrin-conjugated anti-CD34 (Milteny Biotec); mono-
clonal phycoerythrin-conjugated anti-CD13; monoclonal
anti-CD90 (BD Biosciences Pharmigen), CD73 (BD Bio-
sciences Pharmigen), CD105 (DAKO) and CD11b
(DAKO). Non-conjugated mAbs were stained after wash-
ing in 0.1% BSA/PBS with FITC-conjugated anti-mouse
IgG (1:1000, Chemicon). After washing, cell fluorescence
signals were determined immediately using a FACScan
flow cytometer (Becton Dickinson, San Jose, CA, USA)
equipped with an argon laser emission of 488 nm. The
analysis was performed using CellQuest Software (Becton
Dickinson, San Jose, CA, USA).
Scanning Electron Microscopy (SEM)
Cultured cells were prefixed in a solution containing 1%
paraformaldeyde, 1.5% glutaraldehyde in 0.15 M
cacodylate buffer for 2 hours at room temperature. After
washes with PBS, samples were dehydrated with acetone
and critical point dried using carbondioxide. Specimens
were then briefly coated with platinum in a Emitek K575-
E sputtering apparatus and observed with a Hitachi S4000
FE scanning electron microscope.
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